Trial Profile
To compare relapse rates and quality of life inpatients with relapse remitting multiple sclerosis treated with natalizumab or interferon beta or glatiramer acetate
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Dec 2018
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 01 Dec 2018 New trial record